US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma major Sanofi (Euronext: SAN) on Saturday presented ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved ...

1 Dupilumab is being jointly developed by Regeneron ... competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s ...

Hyperpolarized xenon MRI may be useful in assessing response to biologic treatment among patients with asthma, according to a ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

This is well above NICE's upper cost-effectiveness threshold of £30,000 per QALY gained. The committee concluded that dupilumab does not represent a cost-effective use of resources, so could not ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs The agreement includes proposed biosimilars to ...

The TL1A drug would serve as a companion to Sanofi and partner Regeneron's multibillion-dollar blockbuster Dupixent (dupilumab), which ... sharing development costs. Novo Nordisk's long-acting ...

Conclusions: Dupilumab is an effective and well-tolerated treatment for ... This study highlights the importance of generating local data to optimize cost-effectiveness models for health interventions ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...